Sign in to view content

3-Year Update for the Phase 3 Voretigene Neparvovecrzyl Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease

Stephen R. Russell, MD

Video
Published 2018

Related

High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of Diabetic Macular Edema
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
On Demand Cases, Courses, and Papers
2019
Do Anti-VEGF Injections Affect the Development of Neovascular AMD in Fellow Eyes? A Meta-analysis of Clinical Trials
Robert L. Avery, MD
Annual Meeting Talks
2018
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024

Category: Hereditary Retinal Disease & Genetics

See more